Development and refinement of a technique using a medical radiation therapy facility to irradiate immunodeficient mice bearing xenografted human tumours

Translational Research Laboratory, Catalan Institute of Oncology and IDIBELL, Avinguda Gran Via de l'Hospitalet, 199-203, 08907 l'Hospitalet de Llobregat, Spain.
Laboratory Animals (Impact Factor: 0.8). 06/2012; 46(4):345-8. DOI: 10.1258/la.2012.011147
Source: PubMed

ABSTRACT The need for using immunodeficient mice for xenoimplantation of tumours is increasing in translational research in radiation oncology. However, adverse effects of radiation and infectious diseases may ruin the experimental work, in particular when appropriate facilities are not available. In this report, we describe a procedure to deliver fractionated radiotherapy to xenoimplanted tumours in immunodeficient mice using a medical linear accelerator, a method that was devised as an alternative to the lack of facilities devoted to radiation research. The mice were irradiated under anaesthesia and aseptic conditions. Thirty Gray in 10 days using a 6 MV photon beam were delivered only to the right thigh of the mice where tumours were implanted. The mice were evaluated twice a week up to planned euthanasia. The follow-up of mice was completed without premature interruption due to toxicities or infectious diseases, an observation which demonstrates the feasibility of the method.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Für die translationale Krebsforschung sind präklinische in-vivo-Untersuchungen an Kleintieren unverzichtbar, um Erkenntnisse aus in-vitro-Zellexperimenten vor der klinischen Einführung zu validieren. Bei der Konzeption solcher Tierexperimente müssen verschiedene biologische, technische und methodische Aspekte betrachtet werden. Dieser Übersichtsartikel gibt eine umfangreiche Zusammenfassung zur Bestrahlung von Kleintieren wie Mäusen und Ratten basierend auf relevanten Publikationen dieses Forschungsgebietes. Klinische Bestrahlungsgeräte für Teletherapie und Brachtytherapie sowie dedizierte Bestrahlungsgeräte für die Forschung sind zur Bestrahlung von Kleintieren geeignet. Dies hängt jedoch wesentlich vom Tiermodell und den Forschungszielen ab. Geeignete Lösungen werden vorgestellt, welche die verfügbaren Technologien der humanen Strahlentherapie auf die präklinische Forschung mit Kleintieren übertragen. Des Weiteren werden wichtige Entscheidungshilfen für die Experimentplanung zusammengefasst, die zur Erzielung zuverlässiger, klinisch relevanter Ergebnisse zu beachten sind.
    Zeitschrift für Medizinische Physik 08/2014; DOI:10.1016/j.zemedi.2014.07.004 · 1.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Cetuximab is often combined with radiotherapy in advanced SCCHN. Alternative routes bypassing inhibition of EGFR with cetuximab may overshadow the efficacy of this combination. We undertook this study to investigate a possible role of dasatinib in this scenario.Methods:The SCC5, SCC25, SCC29, FaDu and A431 cell lines were assessed in vitro for cell proliferation under cetuximab and dasatinib treatments. In FaDu and A431 cells, dasatinib plus cetuximab resulted in higher proliferation than cetuximab alone. Then, FaDu and A431 cells were implanted into subcutaneous tissue of athymic mice that were irradiated with 30 Gy in 10 fractions over 2 weeks, and treated with cetuximab and dasatinib. Tumour growth, DNA synthesis and angiogenesis were determined. The EGFR, RAS-GTP activity, phosphorylated AKT, ERK1/2, SRC protein levels and VEGF secretion were determined in vitro.Results:The addition of dasatinib to cetuximab and radiotherapy increased tumour growth, DNA synthesis and angiogenesis that were associated with RAS, AKT and ERK1/2 activation, and SRC inhibition in FaDu and A431 cells.Conclusions:In xenografts derived from these two cell lines, dasatinib did not improve the efficacy of cetuximab combined with radiotherapy. On the contrary, it worsened tumour control achieved by the combination of these two treatments.British Journal of Cancer ;advance online publication, 31 July 2014; doi:10.1038/bjc.2014.432
    British Journal of Cancer 07/2014; DOI:10.1038/bjc.2014.432 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Radiotherapy delivered with the antibody cetuximab is a standard treatment option for locally advanced head and neck cancer. Cetuximab acts by blocking epidermal growth factor receptor (EGFR) signaling to inhibit cancer progression. However, a significant percentage of patients will not respond satisfactorily to radiotherapy and cetuximab. Statins reduce the synthesis rate of cholesterol and isoprenoid derivates that may be required for an efficient cell signaling mediated by EGFR. We pre-clinically assessed whether the statin simvastatin could improve this combined therapy. In vitro, simvastatin enhanced the effects of radiotherapy alone and in combination with cetuximab in wound healing, cell proliferation, and clonogenic assays in FaDu cells. These results were reflected in xenoimplanted tumors growing into subcutaneous tissue of athymic mice where concomitant treatment with simvastatin decreased tumor growth. Consistently, lower levels of the phosphorylated ERK1/2, AKT and STAT3 oncoproteins, and higher levels of caspase-3 and apoptosis in cell cultures and xenografts were observed. The EGFR overexpressing A431 cell line was used to reproduce these antitumor effects of simvastatin. Our findings suggest that simvastatin may improve the efficiency of concomitant radiotherapy and cetuximab. Further investigation in the treatment of locally advanced tumors such as head and neck cancer is warranted.
    Translational oncology 08/2014; DOI:10.1016/j.tranon.2014.02.008 · 3.40 Impact Factor


Available from
Aug 5, 2014